NanOlogy Publishes Research Articles on the Immunomodulatory Effects of its Large Surface Area Microparticle Investigational Drugs
NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the IASLC North America Conference on Lung Cancer
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting
Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer
NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer
OncLive: LSAM-PTX Demonstrates Disease Control, Safety in Locally Advanced Pancreatic Cancer
OncLive: LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach
Target Oncology: Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC
JACS: Surgery is a viable treatment for pancreatic cancer patients especially after chemotherapy
Current Urology Reports: Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage
Drug Development Technology: NanOlogy Starts Enrollment in NanoDoce’s Phase I/II Trial
NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019
IASLC Poster 2023: Phase 2a Intratumoral Large Surface Area Microparticle Paclitaxel in Stage 3/4 Lung Cancer
SITC 2023 Poster: Local Administration of Large Surface Area Microparticle Docetaxel is Associated with Anti-tumor Immunomodulation Across Multiple Tumor Types
AACR Pancreatic Cancer 2023 Poster: EUS-guided Local Administration of Large Surface Area Microparticle Paclitaxel with Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer: A Single Center Experience
AACR Pancreatic Cancer 2023 Poster: Enhancing the Immune Response in Locally Advanced Pancreatic Cancer (LAPC) with Intratumoral Endoscopic Ultrasound-guided Fine Needle Injection of Large Surface Area Microparticle Paclitaxel (LSAM-PTX)
ASCO 2023 Abstract: Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies
JDDG: Cutaneous metastases: From epidemiology to therapy
Journal for ImmunoTherapy of Cancer: Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Pancreatology: Intracystic injection of large surface area microparticle paclitaxel for chemoablation of intraductal papillary mucinous neoplasms: Insights from an expanded access protocol
Oncol Ther: Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies
International Journal of Nanomedicine: Intratumoral Treatment of Melanoma Tumors with Large Surface Area Microparticle Paclitaxel and Synergy with Immune Checkpoint Inhibition
